Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients

被引:193
作者
Jordan, SC
Vo, A
Bunnapradist, S
Toyoda, M
Peng, A
Puliyanda, D
Kamil, E
Tyan, D
机构
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Renal Transplant Program, Sch Med, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Transplant Immunol Lab, Sch Med, Los Angeles, CA 90048 USA
[3] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Immunogenet Lab, Sch Med, Los Angeles, CA 90048 USA
关键词
D O I
10.1097/01.TP.0000080685.31697.FC
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Sensitization to human leukocyte antigens (HLA) is a significant barrier to transplantation. Currently, no proven therapy exists to improve access to transplantation for highly sensitized patients. Here, we report a novel approach using intravenous immune globulin to modulate anti-HILA antibody and improve the chances for successful transplantation. Patients and methods. Forty-five highly HILA-sensitized patients presented as candidates for living-donor kidney transplantation (n=28), cadaveric kidney transplantation (n=15), or heart transplantation (n=2). All patients had a positive CDC crossmatch (CMX) with their donors. In living-donor recipients, intravenous immune globulin (MG) was added to the CMX evaluation to determine whether blocking antibodies present in MG could inhibit cytotoxicity. For those who showed in vitro inhibition with MG (n=26), WIG was administered (usually as a single dose, 2 g/kg) and the CDC CMX was repeated against the prospective donor immediately after MG infusion. If negative, the patient underwent transplantation with their living-donor kidney within 24 to 72 hr. A similar but modified protocol was performed for cadaver donor candidates, all of whom were highly sensitized and had had CMX positivity with multiple donors, negating transplantation. Reductions in CMX positivity, posttransplantation serum creatinine level, number and severity of rejection episodes, and patient and graft survival rates were determined. Results. Forty-two patients underwent transplantation. WIG treatment completely abrogated the donor-specific CMXs in 35 of 42 patients. In the remaining 7 patients, the CDC CMX was inhibited, but flow cytometry CMXs remained positive. A total of 13 (31%) of 42 recipients developed rejection episodes 3 to 49 days after transplantation. Three grafts (7%) were lost to rejection. Mean serum creatinine level at 24 months was 1.4.0.4 mg/dL. Patient and graft survival rates were 97.6% and 89.1%, respectively, at 24 months. Conclusions. The in vitro IVIG CMX technique predicts the ability of IVIG to reduce anti-HLA antibody levels in highly sensitized patients. Subsequent in vivo WIG treatment of responders eliminates the positive CDC CMX and allows for successful transplantation. Thus a positive CMX result is not necessarily a contraindication for transplantation and allows access to transplantation for patients for whom it was previously contraindicated.
引用
收藏
页码:631 / 636
页数:6
相关论文
共 29 条
[1]   POOLED HUMAN-IGG MODULATES CYTOKINE PRODUCTION IN LYMPHOCYTES AND MONOCYTES [J].
ANDERSSON, U ;
BJORK, L ;
SKANSENSAPHIR, U ;
ANDERSSON, J .
IMMUNOLOGICAL REVIEWS, 1994, 139 :21-42
[2]   A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection [J].
Casadei, DH ;
Rial, MD ;
Opelz, G ;
Golberg, JC ;
Argento, JA ;
Greco, G ;
Guardia, OE ;
Haas, E ;
Raimondi, EH .
TRANSPLANTATION, 2001, 71 (01) :53-58
[3]   Fc receptor biology [J].
Daeron, M .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :203-234
[4]  
DeMarco T, 1997, J HEART LUNG TRANSPL, V16, P360
[5]   SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIG) - A POTENTIAL TOOL FOR TRANSPLANTATION OF IMMUNIZED PATIENTS [J].
GLOTZ, D ;
HAYMANN, JP ;
SANSONETTI, N ;
FRANCOIS, A ;
MENOYOCALONGE, V ;
BARIETY, J ;
DRUET, P .
TRANSPLANTATION, 1993, 56 (02) :335-337
[6]  
GLOTZ D, 1995, TRANSPLANT P, V27, P1038
[7]   Improved graft survival after renal transplantation in the United States, 1988 to 1996. [J].
Hariharan, S ;
Johnson, CP ;
Bresnahan, BA ;
Taranto, SE ;
McIntosh, MJ ;
Stablein, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) :605-612
[8]   Post-transplant renal function in the first year predicts long-term kidney transplant survival [J].
Hariharan, S ;
McBride, MA ;
Cherikh, WS ;
Tolleris, CB ;
Bresnahan, BA ;
Johnson, CP .
KIDNEY INTERNATIONAL, 2002, 62 (01) :311-318
[9]  
Hurez V, 1994, Ther Immunol, V1, P269
[10]  
JORDAN S C, 1991, Journal of the American Society of Nephrology, V2, P803